{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:24:59Z","timestamp":1788672299483,"version":"build-2803163510"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Signal transduction pathways are important in physiology and pathophysiology. Targeted drugs aim at modifying pathogenic pathway activity, e.g., in cancer. Optimal treatment choice requires assays to measure pathway activity in individual patient tissue or cell samples. We developed a method enabling quantitative measurement of functional pathway activity based on Bayesian computational model inference of pathway activity from measurements of\n                    <jats:italic>mRNA levels of target genes of the pathway-associated transcription factor<\/jats:italic>\n                    . Oestrogen receptor, Wnt, and PI3K-FOXO pathway assays have been described previously. Here, we report model development for androgen receptor, Hedgehog, TGF\u03b2, and NF\u03baB pathway assays, biological validation on multiple cell types, and analysis of data from published clinical studies (multiple sclerosis, amyotrophic lateral sclerosis, contact dermatitis, Ewing sarcoma, lymphoma, medulloblastoma, ependymoma, skin and prostate cancer). Multiple pathway analysis of clinical prostate cancer (PCa) studies showed increased AR activity in hyperplasia and primary PCa but variable AR activity in castrate resistant (CR) PCa, loss of TGF\u03b2 activity in PCa, increased Wnt activity in TMPRSS2:ERG fusion protein-positive PCa, active PI3K pathway in advanced PCa, and active PI3K and NF\u03baB as potential hormonal resistance pathways. Potential value for future clinical practice includes disease subtyping and prediction and targeted therapy response prediction and monitoring.\n                  <\/jats:p>","DOI":"10.1038\/s41598-018-38179-x","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T06:05:41Z","timestamp":1549519541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types"],"prefix":"10.1038","volume":"9","author":[{"given":"Anja","family":"van de Stolpe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Holtzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk","family":"van Ooijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia Alves de","family":"Inda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Verhaegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,7]]},"reference":[{"key":"38179_CR1","unstructured":"Lewis C., Hunter, T., Sever, R. & Thorner, J. (eds) Signal transduction: principles, pathways, and processes. (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 2014)."},{"key":"38179_CR2","doi-asserted-by":"crossref","unstructured":"Thorner, J., Hunter, T., Cantley, L. C. & Sever, R. Signal Transduction: From the Atomic Age to the Post-Genomic Era. Cold Spring Harb. Perspect. Biol. 6, (2014).","DOI":"10.1101\/cshperspect.a022913"},{"key":"38179_CR3","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"38179_CR4","doi-asserted-by":"crossref","first-page":"dev165399","DOI":"10.1242\/dev.165399","volume":"145","author":"CA Chac\u00f3n-Mart\u00ednez","year":"2018","unstructured":"Chac\u00f3n-Mart\u00ednez, C. A., Koester, J. & Wickstr\u00f6m, S. A. Signaling in the stem cell niche: regulating cell fate, function and plasticity. Development 145, dev165399 (2018).","journal-title":"Development"},{"key":"38179_CR5","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","volume":"7","author":"C Massard","year":"2017","unstructured":"Massard, C. et al. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat AdvancedCancers: Results of the MOSCATO 01 Trial. Cancer Discov. 7, 586\u2013595 (2017).","journal-title":"Cancer Discov."},{"key":"38179_CR6","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1158\/0008-5472.CAN-13-2515","volume":"74","author":"W Verhaegh","year":"2014","unstructured":"Verhaegh, W. et al. Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways. Cancer Res. 74, 2936\u20132945 (2014).","journal-title":"Cancer Res."},{"key":"38179_CR7","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.18632\/oncotarget.2276","volume":"5","author":"W Verhaegh","year":"2014","unstructured":"Verhaegh, W. & de Stolpe, V. A. Knowledge-based computational models. Oncotarget 5, 5196\u20135197 (2014).","journal-title":"Oncotarget"},{"key":"38179_CR8","doi-asserted-by":"crossref","unstructured":"Ooijen, H. et al. Assessment of functional PI3K pathway activity in cancer tissue using FOXO target gene expression in a knowledge-based computational model. Am. J. Pathol. 188, 1956\u20131972 (2018).","DOI":"10.1016\/j.ajpath.2018.05.020"},{"key":"38179_CR9","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0092-8674(95)90199-X","volume":"83","author":"DJ Mangelsdorf","year":"1995","unstructured":"Mangelsdorf, D. J. et al. The nuclear receptor superfamily: the second decade. Cell 83, 835\u2013839 (1995).","journal-title":"Cell"},{"key":"38179_CR10","doi-asserted-by":"crossref","unstructured":"Sever, R. & Glass, C. K. Signaling by Nuclear Receptors. Cold Spring Harb. Perspect. Biol. 5 (2013).","DOI":"10.1101\/cshperspect.a016709"},{"key":"38179_CR11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/35077219","volume":"411","author":"J Taipale","year":"2001","unstructured":"Taipale, J. & Beachy, P. A. The Hedgehog and Wnt signalling pathways in cancer. Nature 411, 349\u2013354 (2001).","journal-title":"Nature"},{"key":"38179_CR12","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1126\/science.1098020","volume":"304","author":"L Lum","year":"2004","unstructured":"Lum, L. & Beachy, P. A. The Hedgehog response network: sensors, switches, and routers. Science 304, 1755\u20131759 (2004).","journal-title":"Science"},{"key":"38179_CR13","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2174\/156652409789105570","volume":"9","author":"Y Katoh","year":"2009","unstructured":"Katoh, Y. & Katoh, M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr. Mol. Med. 9, 873\u2013886 (2009).","journal-title":"Curr. Mol. Med."},{"key":"38179_CR14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","volume":"134","author":"J Massagu\u00e9","year":"2008","unstructured":"Massagu\u00e9, J. TGFbeta in Cancer. Cell 134, 215\u2013230 (2008).","journal-title":"Cell"},{"key":"38179_CR15","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1038\/onc.2012.321","volume":"32","author":"DW-C Chen","year":"2012","unstructured":"Chen, D. W.-C., Saha, V., Liu, J.-Z., Schwartz, J.-M. & Krstic-Demonacos, M. Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia. Oncogene 32, 3039 (2012).","journal-title":"Oncogene"},{"key":"38179_CR16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41580-018-0007-0","volume":"19","author":"CJ David","year":"2018","unstructured":"David, C. J. & Massagu\u00e9, J. Contextual determinants of TGF\u03b2 action in development, immunity and cancer. Nat. Rev. Mol. Cell Biol. 19, 419\u2013435 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"38179_CR17","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.immunol.14.1.649","volume":"14","author":"AS Baldwin","year":"1996","unstructured":"Baldwin, A. S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14, 649\u2013683 (1996).","journal-title":"Annu. Rev. Immunol."},{"key":"38179_CR18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1600-065X.2012.01099.x","volume":"246","author":"JA DiDonato","year":"2012","unstructured":"DiDonato, J. A., Mercurio, F. & Karin, M. NF-\u03baB and the link between inflammation and cancer. Immunol. Rev. 246, 379\u2013400 (2012).","journal-title":"Immunol. Rev."},{"key":"38179_CR19","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1126\/science.1109083","volume":"308","author":"MAG Essers","year":"2005","unstructured":"Essers, M. A. G. et al. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 308, 1181\u20131184 (2005).","journal-title":"Science"},{"key":"38179_CR20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nmeth.3252","volume":"12","author":"W Huber","year":"2015","unstructured":"Huber, W. et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat. Methods 12, 115\u2013121 (2015).","journal-title":"Nat. Methods"},{"key":"38179_CR21","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","volume":"169","author":"R Nusse","year":"2017","unstructured":"Nusse, R. & Clevers, H. Wnt\/\u03b2-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell 169, 985\u2013999 (2017).","journal-title":"Cell"},{"key":"38179_CR22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.seminoncol.2004.01.004","volume":"31","author":"BS Katzenellenbogen","year":"2004","unstructured":"Katzenellenbogen, B. S. & Frasor, J. Therapeutic targeting in the estrogen receptor hormonal pathway. Semin. Oncol. 31, 28\u201338 (2004).","journal-title":"Semin. Oncol."},{"key":"38179_CR23","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nri1488","volume":"4","author":"PJ Coffer","year":"2004","unstructured":"Coffer, P. J. & Burgering, B. M. T. Forkhead-box transcription factors and their role in the immune system. Nat. Rev. Immunol. 4, 889\u2013899 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"38179_CR24","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/onc.2008.29","volume":"27","author":"BMT Burgering","year":"2008","unstructured":"Burgering, B. M. T. A brief introduction to FOXOlogy. Oncogene 27, 2258\u20132262 (2008).","journal-title":"Oncogene"},{"key":"38179_CR25","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/19328","volume":"398","author":"GJ Kops","year":"1999","unstructured":"Kops, G. J. et al. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398, 630\u2013634 (1999).","journal-title":"Nature"},{"key":"38179_CR26","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1093\/bioinformatics\/bti605","volume":"21","author":"CL Wilson","year":"2005","unstructured":"Wilson, C. L. & Miller, C. J. Simpleaffy: a BioConductor package for Affymetrix Quality Control and data analysis. Bioinforma. Oxf. Engl. 21, 3683\u20133685 (2005).","journal-title":"Bioinforma. Oxf. Engl."},{"key":"38179_CR27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1089\/omi.2006.10.358","volume":"10","author":"S Heber","year":"2006","unstructured":"Heber, S. & Sick, B. Quality assessment of Affymetrix GeneChip data. Omics J. Integr. Biol. 10, 358\u2013368 (2006).","journal-title":"Omics J. Integr. Biol."},{"key":"38179_CR28","unstructured":"Parman, C. et al. AffyQCReport: QC report generation for affyBatch objects. R package version 1.58.0 (2018)."},{"key":"38179_CR29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/bioinformatics\/btg405","volume":"20","author":"L Gautier","year":"2004","unstructured":"Gautier, L., Cope, L., Bolstad, B. M. & Irizarry, R. A. affy\u2013analysis of Affymetrix GeneChip data at the probe level. Bioinforma. Oxf. Engl. 20, 307\u2013315 (2004).","journal-title":"Bioinforma. Oxf. Engl."},{"key":"38179_CR30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/hmg\/10.7.757","volume":"10","author":"AE Bale","year":"2001","unstructured":"Bale, A. E. & Yu, K. P. The hedgehog pathway and basal cell carcinomas. Hum. Mol. Genet. 10, 757\u2013762 (2001).","journal-title":"Hum. Mol. Genet."},{"key":"38179_CR31","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1158\/0008-5472.CAN-15-3490","volume":"77","author":"G Valenti","year":"2017","unstructured":"Valenti, G. et al. Cancer Stem Cells Regulate Cancer-Associated Fibroblasts via Activation of Hedgehog Signaling in Mammary Gland Tumors. Cancer Res. 77, 2134\u20132147 (2017).","journal-title":"Cancer Res."},{"key":"38179_CR32","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00401-011-0922-z","volume":"123","author":"MD Taylor","year":"2012","unstructured":"Taylor, M. D. et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. (Berl.) 123, 465\u2013472 (2012).","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"38179_CR33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ccr.2014.02.004","volume":"25","author":"M Kool","year":"2014","unstructured":"Kool, M. et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 25, 393\u2013405 (2014).","journal-title":"Cancer Cell"},{"key":"38179_CR34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jb\/mvr136","volume":"151","author":"M Kawata","year":"2012","unstructured":"Kawata, M. et al. TGF-\u03b2-induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by pro-inflammatory cytokines derived from RAW 264.7 macrophage cells. J. Biochem. (Tokyo) 151, 205\u2013216 (2012).","journal-title":"J. Biochem. (Tokyo)"},{"key":"38179_CR35","doi-asserted-by":"crossref","unstructured":"\u00a0Hedrick, E., Mohankumar, K. & Safe, S. TGF \u03b2-induced Lung Cancer Cell Migration Is NR4A1-dependent. Mol. Cancer Res. 16, 1991-2002 (2018)","DOI":"10.1158\/1541-7786.MCR-18-0366"},{"key":"38179_CR36","doi-asserted-by":"crossref","first-page":"E1480","DOI":"10.1073\/pnas.1615065114","volume":"114","author":"D Lukas","year":"2017","unstructured":"Lukas, D. et al. TGF-\u03b2 inhibitor Smad7 regulates dendritic cell-induced autoimmunity. Proc. Natl. Acad. Sci. 114, E1480\u2013E1489 (2017).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"38179_CR37","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","volume":"459","author":"M Compagno","year":"2009","unstructured":"Compagno, M. et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459, 717\u2013721 (2009).","journal-title":"Nature"},{"key":"38179_CR38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3960\/jslrt.50.45","volume":"50","author":"Y Suzuki","year":"2010","unstructured":"Suzuki, Y. et al. Constitutive activity of nuclear transcription factor kappaB is observed in follicular lymphoma. J. Clin. Exp. Hematop. JCEH 50, 45\u201350 (2010).","journal-title":"J. Clin. Exp. Hematop. JCEH"},{"key":"38179_CR39","first-page":"1331","volume":"27","author":"L Odqvist","year":"2014","unstructured":"Odqvist, L. et al. NF\u03baB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc 27, 1331\u20131337 (2014).","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc"},{"issue":"Pt 1","key":"38179_CR40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1042\/bj3040087","volume":"304","author":"M Frankenberger","year":"1994","unstructured":"Frankenberger, M. et al. Constitutive nuclear NF-kappa B in cells of the monocyte lineage. Biochem. J. 304(Pt 1), 87\u201394 (1994).","journal-title":"Biochem. J."},{"key":"38179_CR41","first-page":"1834","volume":"175","author":"T Ear","year":"2005","unstructured":"Ear, T., Cloutier, A. & McDonald, P. P. Constitutive nuclear expression of the I kappa B kinase complex and its activation in human neutrophils. J. Immunol. Baltim. Md 1950 175, 1834\u20131842 (2005).","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"38179_CR42","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1006\/mcbr.2000.0219","volume":"3","author":"G Rimbach","year":"2000","unstructured":"Rimbach, G., Valacchi, G., Canali, R. & Virgili, F. Macrophages stimulated with IFN-gamma activate NF-kappa B and induce MCP-1 gene expression in primary human endothelial cells. Mol. Cell Biol. Res. Commun. MCBRC 3, 238\u2013242 (2000).","journal-title":"Mol. Cell Biol. Res. Commun. MCBRC"},{"key":"38179_CR43","first-page":"4461","volume":"181","author":"V Vila-del Sol","year":"2008","unstructured":"Vila-del Sol, V., Punz\u00f3n, C. & Fresno, M. IFN-gamma-induced TNF-alpha expression is regulated by interferon regulatory factors 1 and 8 in mouse macrophages. J. Immunol. Baltim. Md 1950 181, 4461\u20134470 (2008).","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"38179_CR44","doi-asserted-by":"crossref","first-page":"6746","DOI":"10.1128\/MCB.17.11.6746","volume":"17","author":"JL Cheshire","year":"1997","unstructured":"Cheshire, J. L. & Baldwin, A. S. Synergistic activation of NF-kappaB by tumor necrosis factor alpha and gamma interferon via enhanced I kappaB alpha degradation and de novo I kappaBbeta degradation. Mol. Cell. Biol. 17, 6746\u20136754 (1997).","journal-title":"Mol. Cell. Biol."},{"key":"38179_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0898-6568(02)00080-3","volume":"15","author":"S Bell","year":"2003","unstructured":"Bell, S. et al. Involvement of NF-kappaB signalling in skin physiology and disease. Cell. Signal. 15, 1\u20137 (2003).","journal-title":"Cell. Signal."},{"key":"38179_CR46","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jaci.2014.03.009","volume":"134","author":"N Dhingra","year":"2014","unstructured":"Dhingra, N. et al. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J. Allergy Clin. Immunol. 134, 362\u2013372 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"38179_CR47","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1158\/1078-0432.CCR-05-2800","volume":"12","author":"SJ Van Laere","year":"2006","unstructured":"Van Laere, S. J. et al. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 12, 3249\u20133256 (2006).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"38179_CR48","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","volume":"15","author":"CA Dendrou","year":"2015","unstructured":"Dendrou, C. A., Fugger, L. & Friese, M. A. Immunopathology of multiple sclerosis. Nat. Rev. Immunol. 15, 545\u2013558 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"38179_CR49","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.molmed.2013.08.001","volume":"19","author":"C Mc Guire","year":"2013","unstructured":"Mc Guire, C., Prinz, M., Beyaert, R. & van Loo, G. Nuclear factor kappa B (NF-\u03baB) in multiple sclerosis pathology. Trends Mol. Med. 19, 604\u2013613 (2013).","journal-title":"Trends Mol. Med."},{"key":"38179_CR50","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/path.4826","volume":"241","author":"DN Rodrigues","year":"2017","unstructured":"Rodrigues, D. N. et al. The molecular underpinnings of prostate cancer: impacts on management and pathology practice. J. Pathol. 241, 173\u2013182 (2017).","journal-title":"J. Pathol."},{"key":"38179_CR51","first-page":"3","volume":"37","author":"RA Davey","year":"2016","unstructured":"Davey, R. A. & Grossmann, M. Androgen ReceptorStructure, Function and Biology: From Bench to Bedside. Clin. Biochem. Rev. 37, 3\u201315 (2016).","journal-title":"Clin. Biochem. Rev."},{"key":"38179_CR52","doi-asserted-by":"crossref","first-page":"9074","DOI":"10.1074\/jbc.M806233200","volume":"284","author":"E Beauchamp","year":"2009","unstructured":"Beauchamp, E. et al. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J. Biol. Chem. 284, 9074\u20139082 (2009).","journal-title":"J. Biol. Chem."},{"key":"38179_CR53","doi-asserted-by":"crossref","first-page":"e7608","DOI":"10.1371\/journal.pone.0007608","volume":"4","author":"J Joo","year":"2009","unstructured":"Joo, J. et al. GLI1 is a central mediator of EWS\/FLI1 signaling in Ewing tumors. PloS One 4, e7608 (2009).","journal-title":"PloS One"},{"key":"38179_CR54","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nn.3357","volume":"16","author":"SH Kang","year":"2013","unstructured":"Kang, S. H. et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 16, 571\u2013579 (2013).","journal-title":"Nat. Neurosci."},{"key":"38179_CR55","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.mayocp.2018.04.007","volume":"93","author":"B Oskarsson","year":"2018","unstructured":"Oskarsson, B., Gendron, T. F. & Staff, N. P. Amyotrophic Lateral Sclerosis: An Update for 2018. Mayo Clin. Proc. 93, 1617\u20131628 (2018).","journal-title":"Mayo Clin. Proc."},{"key":"38179_CR56","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pneurobio.2018.07.004","volume":"169","author":"I Ferrer","year":"2018","unstructured":"Ferrer, I. Oligodendrogliopathy in neurodegenerative diseases with abnormal protein aggregates: The forgotten partner. Prog. Neurobiol. 169, 24\u201354 (2018).","journal-title":"Prog. Neurobiol."},{"key":"38179_CR57","doi-asserted-by":"crossref","unstructured":"Peters, S. et al. The TGF-\u03b2 System As a Potential Pathogenic Player in Disease Modulation of Amyotrophic Lateral Sclerosis. Front. Neurol. 8 (2017).","DOI":"10.3389\/fneur.2017.00669"},{"key":"38179_CR58","doi-asserted-by":"crossref","first-page":"7917","DOI":"10.1523\/JNEUROSCI.0363-14.2014","volume":"34","author":"J Palazuelos","year":"2014","unstructured":"Palazuelos, J., Klingener, M. & Aguirre, A. TGF\u03b2 signaling regulates the timing of CNS myelination by modulating oligodendrocyte progenitor cell cycle exit through SMAD3\/4\/FoxO1\/Sp1. J. Neurosci. Off. J. Soc. Neurosci. 34, 7917\u20137930 (2014).","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"38179_CR59","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccr.2011.07.007","volume":"20","author":"H Witt","year":"2011","unstructured":"Witt, H. et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20, 143\u2013157 (2011).","journal-title":"Cancer Cell"},{"key":"38179_CR60","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"38179_CR61","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"DW Huang","year":"2009","unstructured":"Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44\u201357 (2009).","journal-title":"Nat. Protoc."},{"key":"38179_CR62","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0092-8674(00)00122-7","volume":"103","author":"M Bienz","year":"2000","unstructured":"Bienz, M. & Clevers, H. Linking colorectal cancer to Wnt signaling. Cell 103, 311\u2013320 (2000).","journal-title":"Cell"},{"key":"38179_CR63","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1126\/science.1104815","volume":"307","author":"F Radtke","year":"2005","unstructured":"Radtke, F. & Clevers, H. Self-renewal and cancer of the gut: two sides of a coin. Science 307, 1904\u20131909 (2005).","journal-title":"Science"},{"key":"38179_CR64","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/ng.1085","volume":"44","author":"S Postel-Vinay","year":"2012","unstructured":"Postel-Vinay, S. et al. Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat. Genet. 44, 323\u2013327 (2012).","journal-title":"Nat. Genet."},{"key":"38179_CR65","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1172\/JCI45692","volume":"121","author":"GP Raju","year":"2011","unstructured":"Raju, G. P. Arsenic: a potentially useful poison for Hedgehog-driven cancers. J. Clin. Invest. 121, 14\u201316 (2011).","journal-title":"J. Clin. Invest."},{"key":"38179_CR66","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41593-018-0121-5","volume":"21","author":"EG Hughes","year":"2018","unstructured":"Hughes, E. G., Orthmann-Murphy, J. L., Langseth, A. J. & Bergles, D. E. Myelin remodeling through experience-dependent oligodendrogenesis in the adult somatosensory cortex. Nat. Neurosci. 21, 696\u2013706 (2018).","journal-title":"Nat. Neurosci."},{"key":"38179_CR67","doi-asserted-by":"crossref","first-page":"E6496","DOI":"10.1073\/pnas.1607496113","volume":"113","author":"L Ferraiuolo","year":"2016","unstructured":"Ferraiuolo, L. et al. Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism. Proc. Natl. Acad. Sci. USA 113, E6496\u2013E6505 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"38179_CR68","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1097\/MD.0000000000000441","volume":"94","author":"Z Jamrozik","year":"2015","unstructured":"Jamrozik, Z., Gawel, M., Szacka, K. & Bakon, L. A case report of amyotrophic lateral sclerosis in a patient with Klippel-Feil syndrome\u2014a familial occurrence: a potential role of TGF-\u03b2 signaling pathway. Medicine (Baltimore) 94, e441 (2015).","journal-title":"Medicine (Baltimore)"},{"key":"38179_CR69","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jns.2012.10.029","volume":"324","author":"S Tetsuka","year":"2013","unstructured":"Tetsuka, S. et al. ZNF512B gene is a prognostic factor in patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 324, 163\u2013166 (2013).","journal-title":"J. Neurol. Sci."},{"key":"38179_CR70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41590-018-0091-5","volume":"19","author":"H Lund","year":"2018","unstructured":"Lund, H. et al. Fatal demyelinating disease is induced by monocyte-derived macrophages in the absence of TGF-\u03b2 signaling. Nat. Immunol. 19, 1\u20137 (2018).","journal-title":"Nat. Immunol."},{"key":"38179_CR71","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.expneurol.2009.02.017","volume":"217","author":"BM Morrison","year":"2009","unstructured":"Morrison, B. M. et al. A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 217, 258\u2013268 (2009).","journal-title":"Exp. Neurol."},{"key":"38179_CR72","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1158\/2326-6066.CIR-15-0061","volume":"3","author":"AM Griesinger","year":"2015","unstructured":"Griesinger, A. M. et al. Interleukin-6\/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma. Cancer Immunol. Res. 3, 1165\u20131174 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"38179_CR73","first-page":"4349","volume":"38","author":"J Geller","year":"1978","unstructured":"Geller, J., Albert, J., de la Vega, D., Loza, D. & Stoeltzing, W. Dihydrotestosterone concentration in prostate cancer tissue as a predictor of tumor differentiation and hormonal dependency. Cancer Res. 38, 4349\u20134352 (1978).","journal-title":"Cancer Res."},{"key":"38179_CR74","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/pros.21034","volume":"69","author":"KJ O\u2019Malley","year":"2009","unstructured":"O\u2019Malley, K. J. et al. The expression of androgen-responsive genes is up-regulated in the epithelia of benign prostatic hyperplasia. The Prostate 69, 1716\u20131723 (2009).","journal-title":"The Prostate"},{"key":"38179_CR75","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1158\/1078-0432.CCR-17-2006","volume":"24","author":"Y Yang","year":"2018","unstructured":"Yang, Y. et al. PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 24, 834\u2013846 (2018).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"38179_CR76","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1200\/EDBK_159248","volume":"35","author":"H Beltran","year":"2016","unstructured":"Beltran, H., Antonarakis, E. S., Morris, M. J. & Attard, G. Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Meet. 35, 131\u2013141 (2016).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Meet."},{"issue":"6","key":"38179_CR77","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/2159-8290.CD-17-0867","volume":"8","author":"Helen B. Pearson","year":"2018","unstructured":"Pearson, H. B. et al. Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth. Cancer Discov., https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0867 (2018).","journal-title":"Cancer Discovery"},{"key":"38179_CR78","doi-asserted-by":"crossref","unstructured":"Crumbaker, M., Khoja, L. & Joshua, A. M. AR Signaling and the PI3K Pathway in Prostate Cancer. Cancers 9 (2017).","DOI":"10.3390\/cancers9040034"},{"key":"38179_CR79","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1541-7786.MCR-14-0569","volume":"13","author":"NE Martin","year":"2015","unstructured":"Martin, N. E. et al. Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Mol. Cancer Res. MCR 13, 1431\u20131440 (2015).","journal-title":"Mol. Cancer Res. MCR"},{"key":"38179_CR80","first-page":"107","volume":"3","author":"A van de Stolpe","year":"2013","unstructured":"van de Stolpe, A. On the origin and destination of cancer stem cells: a conceptual evaluation. Am. J. Cancer Res. 3, 107\u2013116 (2013).","journal-title":"Am. J. Cancer Res."},{"key":"38179_CR81","doi-asserted-by":"crossref","first-page":"e1025181","DOI":"10.1080\/23723556.2015.1025181","volume":"3","author":"H Demagny","year":"2016","unstructured":"Demagny, H. & De Robertis, E. M. Point mutations in the tumor suppressor Smad4\/DPC4 enhance its phosphorylation by GSK3 and reversibly inactivate TGF-\u03b2 signaling. Mol. Cell. Oncol. 3, e1025181 (2016).","journal-title":"Mol. Cell. Oncol."},{"key":"38179_CR82","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1038\/onc.2013.374","volume":"33","author":"S Mishra","year":"2014","unstructured":"Mishra, S. et al. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. Oncogene 33, 4097\u20134106 (2014).","journal-title":"Oncogene"},{"key":"38179_CR83","doi-asserted-by":"crossref","first-page":"7118","DOI":"10.1038\/onc.2008.293","volume":"27","author":"X Li","year":"2008","unstructured":"Li, X. et al. Prostate tumor progression is mediated by a paracrine TGF-beta\/Wnt3a signaling axis. Oncogene 27, 7118\u20137130 (2008).","journal-title":"Oncogene"},{"key":"38179_CR84","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1074\/jbc.M108855200","volume":"277","author":"JE Chipuk","year":"2002","unstructured":"Chipuk, J. E. et al. The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3. J. Biol. Chem. 277, 1240\u20131248 (2002).","journal-title":"J. Biol. Chem."},{"key":"38179_CR85","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nrurol.2012.116","volume":"9","author":"RM Kypta","year":"2012","unstructured":"Kypta, R. M. & Waxman, J. Wnt\/\u03b2-catenin signalling in prostate cancer. Nat. Rev. Urol. 9, 418\u2013428 (2012).","journal-title":"Nat. Rev. Urol."},{"key":"38179_CR86","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.mce.2017.02.008","volume":"462","author":"JA Schneider","year":"2018","unstructured":"Schneider, J. A. & Logan, S. K. Revisiting the role of Wnt\/\u03b2-catenin signaling in prostate cancer. Mol. Cell. Endocrinol. 462, 3\u20138 (2018).","journal-title":"Mol. Cell. Endocrinol."},{"key":"38179_CR87","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1158\/0008-5472.CAN-13-0882","volume":"73","author":"L Wu","year":"2013","unstructured":"Wu, L. et al. ERG is a critical regulator of Wnt\/LEF1 signaling in prostate cancer. Cancer Res. 73, 6068\u20136079 (2013).","journal-title":"Cancer Res."},{"key":"38179_CR88","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.cellsig.2015.01.001","volume":"27","author":"H Liu","year":"2015","unstructured":"Liu, H. et al. FOXO3a modulates WNT\/\u03b2-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells. Cell. Signal. 27, 510\u2013518 (2015).","journal-title":"Cell. Signal."},{"key":"38179_CR89","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm3434","volume":"13","author":"J Massagu\u00e9","year":"2012","unstructured":"Massagu\u00e9, J. TGF\u03b2 signalling in context. Nat. Rev. Mol. Cell Biol. 13, 616\u2013630 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"38179_CR90","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/pros.23195","volume":"76","author":"DC Austin","year":"2016","unstructured":"Austin, D. C. et al. NF-\u03baB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. The Prostate 76, 1004\u20131018 (2016).","journal-title":"The Prostate"},{"key":"38179_CR91","doi-asserted-by":"crossref","first-page":"111084","DOI":"10.18632\/oncotarget.22560","volume":"8","author":"CJ King","year":"2017","unstructured":"King, C. J. et al. Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer. Oncotarget 8, 111084\u2013111095 (2017).","journal-title":"Oncotarget"},{"key":"38179_CR92","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.juro.2015.03.103","volume":"194","author":"KC Torkko","year":"2015","unstructured":"Torkko, K. C. et al. Prostate Biopsy Markers of Inflammation are Associated with Risk of Clinical Progression of Benign Prostatic Hyperplasia: Findings from the MTOPS Study. J. Urol. 194, 454\u2013461 (2015).","journal-title":"J. Urol."},{"key":"38179_CR93","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1055-9965.EPI-13-1126","volume":"23","author":"B Gurel","year":"2014","unstructured":"Gurel, B. et al. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol. 23, 847\u2013856 (2014).","journal-title":"Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"key":"38179_CR94","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.humpath.2011.11.009","volume":"43","author":"L MacKenzie","year":"2012","unstructured":"MacKenzie, L. et al. Nuclear factor \u03baB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor. Hum. Pathol. 43, 1491\u20131500 (2012).","journal-title":"Hum. Pathol."},{"key":"38179_CR95","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1210\/mend.12.1.0044","volume":"12","author":"LI McKay","year":"1998","unstructured":"McKay, L. I. & Cidlowski, J. A. Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: mechanisms of mutual antagonism. Mol. Endocrinol. Baltim. Md 12, 45\u201356 (1998).","journal-title":"Mol. Endocrinol. Baltim. Md"},{"key":"38179_CR96","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(17)30906-3","volume":"19","author":"BA Teply","year":"2018","unstructured":"Teply, B. A. et al. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol. 19, 76\u201386 (2018).","journal-title":"Lancet Oncol."},{"key":"38179_CR97","doi-asserted-by":"crossref","first-page":"A268","DOI":"10.1289\/ehp.1510345","volume":"123","author":"G Langley","year":"2015","unstructured":"Langley, G. et al. Lessons from Toxicology: Developing a 21st-Century Paradigm for Medical Research. Environ. Health Perspect. 123, A268\u2013272 (2015).","journal-title":"Environ. Health Perspect."},{"key":"38179_CR98","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1039\/c3lc50248a","volume":"13","author":"A van de Stolpe","year":"2013","unstructured":"van de Stolpe, A. & den Toonder, J. Workshop meeting report Organs-on-Chips: human disease models. Lab. Chip 13, 3449\u20133470 (2013).","journal-title":"Lab. Chip"}],"updated-by":[{"DOI":"10.1038\/s41598-020-60886-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-38179-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-38179-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-38179-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:48:27Z","timestamp":1671238107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-38179-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,7]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["38179"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-38179-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,7]]},"assertion":[{"value":"6 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are regular employees of Philips Research. A.v.d.S. has Philips stocks. Patents relevant for this publication: Patent applicant: Koninklijke Philips NV: (1) WO2013011479; granted; inventors: W. Verhaegh, A. van de Stolpe, H. van Ooijen, K. Dulla, M.A. Inda, R. Hoffmann; relation to publication: pathway models of Wnt, ER, AR, HH. (2) WO2015101635; granted; inventors: H. van Ooijen, W. Verhaegh, A. van de Stolpe; relation to publication: Pathway model of PI3K\/FOXO. (3) US2018271438; pending; inventors: H. van Ooijen, A. van de Stolpe, D. van Strijp; relation to publication: Pathway model of TGFb. (4) BR112018002848; pending; inventor: H. van Ooijen; relation to publication: Pathway model of NFkB.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1603"}}